CAR-Ms consisting of an scFv targeting HER2, CD19, and mesothelin, a CD8 hinge and transmembrane domain, and a CD3ζ intracellular domain are qualified for enhancing phagocytosis, inducing cytokine release, and increasing anti-tumor activity. The gene discussed is CD19; the disease is neoplasm.